id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-274481-k1dp1ilv	Falavigna, Maicon	Guidelines for the pharmacological treatment of COVID-19. The task-force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology	2020		.txt	text/plain	6973	447	44	Summary of the evidence: the systematic review identified three comparative clinical trials with available data on the effects of hydroxychloroquine (HCQ) in COVID-19 patients: two open randomized clinical trials (29, 30) in a patient population with mild to moderate disease, and one cohort study. Recommendation 2 -we suggest against the routine use the hydroxychloroquine or chloroquine plus azithromycin combination for treatment of COVID-19 patients (weak recommendation; Level of Evidence very low). Recommendation 4 -We suggest the use of empirical oseltamivir treatment in patients with Severe Acute Respiratory Syndrome (SARS) or flu-like syndrome with risk factors for complications when a diagnosis of influenza cannot be ruled out (weak recommendation; Level of Evidence very low). Summary of the evidence -two randomized clinical trials assessed the use of lopinavir/ritonavir in COVID-19 patients.	./cache/cord-274481-k1dp1ilv.txt	./txt/cord-274481-k1dp1ilv.txt